Antimetabolites for cancer treatment

Last updated: November 01, 2022

Antimetabolites for cancer treatment

Watch later

Watch later

Vascular tumors
DNA alkylating medications
Pediatric bone tumors: Clinical
Pediatric gastrointestinal bleeding: Clinical
Down syndrome (Trisomy 21)
Edwards syndrome (Trisomy 18)
Patau syndrome (Trisomy 13)
Fragile X syndrome
Huntington disease
Myotonic dystrophy
Friedreich ataxia
Klinefelter syndrome
Angelman syndrome
Prader-Willi syndrome
Cri du chat syndrome
Williams syndrome
Alport syndrome
Marfan syndrome
von Hippel-Lindau disease
Newborn management: Clinical
Atypical antidepressants
Acid reducing medications
Adrenergic antagonists: Alpha blockers
Cell wall synthesis inhibitors: Penicillins
Protein synthesis inhibitors: Aminoglycosides
Herpesvirus medications
Stevens-Johnson syndrome
Burns
Nonbenzodiazepine anticonvulsants
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Coagulation (secondary hemostasis)
Patau syndrome (Trisomy 13)
Hypothyroidism medications
Spina bifida
Persistent truncus arteriosus
Antimalarials
DNA synthesis inhibitors: Fluoroquinolones
Miscellaneous protein synthesis inhibitors
Ventricular septal defect
Monoamine oxidase inhibitors
Miscellaneous hypoglycemics
Endocarditis: Pathology review
Infective endocarditis: Clinical
Endocarditis
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Fatty acid oxidation
Echinocandins
Haemophilus ducreyi (Chancroid)
Urinary tract infections: Clinical
Movement of water between body compartments
Typical antipsychotics
Cholinomimetics: Indirect agonists (anticholinesterases)
Positive inotropic medications
cGMP mediated smooth muscle vasodilators
Aortic valve disease
Familial hypercholesterolemia
Cardiovascular system anatomy and physiology
Hemophilia
Antimetabolites for cancer treatment
Complement system
Topoisomerase inhibitors
Eye conditions: Inflammation, infections and trauma: Pathology review
Meningitis
Muscle spindles and golgi tendon organs
Ascending and descending spinal tracts
Trigeminal neuralgia
Hypokinetic movement disorders: Clinical
Cerebellum
Basal ganglia: Direct and indirect pathway of movement
Anatomy of the olfactory (CN I) and optic (CN II) nerves
Photoreception
Cholinergic receptors
Hemianopsia
Nervous system anatomy and physiology
Peripheral nervous system histology
Major depressive disorder
Congenital adrenal hyperplasia
Urinary incontinence: Pathology review
Acute respiratory distress syndrome
Anatomy of the abdominal viscera: Large intestine
Congenital gastrointestinal disorders: Pathology review
Somatosensory pathways
Jaundice: Pathology review
Influenza virus
Alveolar surface tension and surfactant
Abnormal heart sounds
Fetal circulation
Total anomalous pulmonary venous return
Anatomy of the anterolateral abdominal wall
Anthelmintic medications
Hernias: Clinical
Cerebrospinal fluid
Vestibulo-ocular reflex and nystagmus
Night terrors
Cannabis use disorder
Sympathetic nervous system
Cocaine use disorder
Complement deficiency
Brown-Sequard Syndrome
Bacillus cereus (Food poisoning)
Deep vein thrombosis and pulmonary embolism: Pathology review
Spinal muscular atrophy
Sleep disorders: Clinical
Lung cancer
Adult brain tumors
Polycystic kidney disease
Pulmonary hypoplasia
Sensitivity and specificity
Developmental milestones: Clinical
Lymphatic system anatomy and physiology
Shaken baby syndrome
Shigella
Beckwith-Wiedemann syndrome
Iron deficiency anemia
Vessels and nerves of the gluteal region and posterior thigh
Emotion
Antidiarrheals
Vascular dementia
Aspergillus fumigatus
Cryptococcus neoformans
Trichuris trichiura (Whipworm)
Multiple endocrine neoplasia
Growth hormone deficiency
Growth and development
Cartilage structure and growth
Pituitary adenoma
Coxsackievirus
Pediatric brain tumors
Gallbladder disorders: Pathology review
Gallbladder disorders: Clinical
Extracellular matrix
Ischemia
Vitamin K deficiency
Jaundice: Clinical
Prebiotics and probiotics
Nucleotide metabolism
Immune thrombocytopenia
Hyperlipidemia
Hypertriglyceridemia
Respiratory syncytial virus
Megaloblastic anemia
Fatty acid synthesis
Multiple myeloma
Waldenstrom macroglobulinemia
Systemic lupus erythematosus
Hypercalcemia
Strongyloides stercoralis
Polycythemia vera (NORD)
Hypokalemia
Metabolic alkalosis
Paracetamol toxicity
Chronic kidney disease
Myelofibrosis (NORD)
Age-related macular degeneration
Myeloproliferative neoplasms: Clinical
Metaplasia and dysplasia
Blood brain barrier
Epidural abscess
Cystinosis
Fat-soluble vitamin deficiency and toxicity: Pathology review
Zinc deficiency and protein-energy malnutrition: Pathology review
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Kidney stones
Pasteurella multocida
Mitosis and meiosis
Haemophilus influenzae
Escherichia coli
Cell membrane
Otitis externa
Primary ciliary dyskinesia
Rheumatic heart disease
Sjogren syndrome: Clinical
Attention deficit hyperactivity disorder
Neonatal ICU conditions: Clinical
Oncogenes and tumor suppressor genes
Muscular system anatomy and physiology
Polycystic ovary syndrome
Azoles
Brain abscess
Disease causality
Entamoeba histolytica (Amebiasis)
Bone tumors
Pediatric infectious rashes: Clinical
Lower back pain: Clinical
Antiphospholipid syndrome
Adrenal insufficiency: Pathology review
Dementia and delirium: Clinical
Eczematous rashes: Clinical
Pulmonary embolism
Syncope: Clinical
Pharyngeal arches, pouches, and clefts
Uterine disorders: Pathology review
Distal convoluted tubule
Antidiuretic hormone
Adrenal hormone synthesis inhibitors
Idiopathic intracranial hypertension
Clinical Skills: Body Temperature Assessment
Toxidromes: Clinical
Anxiolytics and sedative-hypnotics: Nursing pharmacology
Abuse, mistreatment, and neglect
Sensory system: Eye and ear disorders
Vaccinations: Clinical
Anatomy of the orbit
Clinical Skills: High-frequency oscillatory ventilation (HFOV)
Anxiety disorders: Clinical
Primary adrenal insufficiency
Hodgkin lymphoma
Sympatholytics: Alpha-2 agonists
Antidepressants - SSRIs and SNRIs: Nursing pharmacology
Antimetabolites for cancer treatment
Pediatric upper airway conditions: Clinical

Transcript

Watch video only

Antimetabolites are a diverse group of medications that are used for the treatment of various conditions including cancer, infections and autoimmune disorders.

In this video, we are focusing on the antimetabolites used in cancer treatment.

Alright, during the S phase of the cell cycle, the cell performs DNA replication.

DNA is composed of a sequence of deoxyribonucleotides and each deoxyribonucleotide is made out of a phosphate group, a five carbon sugar like deoxyribose, and a nucleobase, which can be either a pyrimidine like cytosine, or thymidine, or a purine like adenine or guanine.

Now, nucleotide synthesis starts with ribose-5-phosphate, which is specific for RNA, and an enzyme called ribose phosphate pyrophosphokinase uses an ATP to remove two phosphate groups from it, attaching them to ribose-5-phosphate, creating a phosphoribosyl pyrophosphate, or PRPP.

Because it catalyzes the synthesis of PRPP, the enzyme ribose phosphate pyrophosphokinase is also known as PRPP synthetase.

Next step is to make pyrimidines. The amino acid glutamine, bicarbonate, and water are used to form a molecule called carbamoyl phosphate which is then joined to aspartate and together, they form a ringed molecule called carbamoyl aspartic acid, which gets dehydrated to create a molecule called orotate.

Next, an enzyme moves the phosphoribose unit from PRPP to orotate and that forms orotidine monophosphate, or OMP.

Next, the enzyme UMP synthase converts orotidine monophosphate into uridine monophosphate, or UMP.

That UMP gets phosphorylated twice by nucleoside diphosphate kinase, to become uridine triphosphate, or UTP.

Finally, the enzyme CTP synthase, converts uridine triphosphate into cytidine triphosphate, or CTP.

Now, purine synthesis starts with the amino acids glutamine, aspartate, and glycine, together with bicarbonate and formate, which is the anion derived from formic acid.

These undergo a ten-step pathway and the result is inosine monophosphate, or IMP, which is sort of a generic purine.

IMP can be converted to AMP and GMP.

Okay, RNA nucleotides are usually in the monophosphate form, but to get to DNA nucleotides, we need them in the diphosphate form, so CDP, UDP, ADP, and GDP.

Next, an enzyme called ribonucleotide diphosphate reductase will reduce the ribose within them into deoxyribose, creating dCDP, dUDP dADP, and dGDP.

After this, they just need to lose a phosphate group, and we’ll have dCMP, dUMP, dAMP, and dGMP.

But, something is missing - dTMP. And here comes the folic acid, or vitamin B9, which is converted to tetrahydrofolic acid, or THF.

THF acts as a mediator and accepts a “methylene” group from the amino acid serine and transfers it to dUMP or deoxyuridine monophosphate.

Then, an enzyme called thymidylate synthetase can convert dUMP to dTMP or deoxythymidine monophosphate, and at that point we’re all set to make DNA.

Now, pyrimidine rings can be degraded completely back down to carbon dioxide (CO2) and ammonia (NH3,) which can then be excreted from the lungs and into urine.

In contrast, purine rings, or G and A are degraded down to the metabolically inert uric acid which is then excreted into urine.

For GMP to become uric acid, the enzyme purine nucleoside phosphorylase, first removes the ribose and the phosphate from it, turning it into guanine.

Next, another enzyme called guanase removes an amine group turning guanine into xanthine.

Finally, xanthine is oxidized into uric acid by the enzyme xanthine oxidase.

On the other hand, for AMP to become uric acid, first the enzyme AMP deaminase removes an amine group from it, turning it into IMP.

Then purine nucleoside phosphorylase comes in and removes the phosphate and the ribose from IMP, making hypoxanthine.

Hypoxanthine is then oxidised twice by xanthine oxidase - first to become xanthine, and then finally, to uric acid.

Now, it turns out that those intermediate molecules in purine degradation, guanine and hypoxanthine, can be restored into fresh new nucleic acids, through what is known as a salvage pathway.

The enzyme hypoxanthine-guanine phosphoribosyl transferase, or HGPRT for short, returns ribose and phosphate back to guanine to form GMP, and to hypoxanthine to form IMP.

Alright, now the cancer cells pretty much do nothing but divide all day long and so they are very sensitive to cytotoxic medications that block DNA synthesis.

The bad news is that plenty of normal cells in our body, like the cells lining the GI tract, and the precursors to blood cells and platelets, are also actively dividing and this explains why anticancer medications are toxic to these tissues.

So the antimetabolites usually disrupt the pathway responsible for DNA synthesis by mimicking nucleobases or folic acid, and cause DNA replication and cell proliferation to come to a halt.

Medications that mimic purine include azathioprine and cladribine, while medications that mimic pyrimidine include cytarabine and 5-fluorouracil. Finally, there's folic acid analogues like methotrexate.

Alright, let’s start with azathioprine which is the prodrug of 6-mercaptopurine, or 6-MP.

Azathioprine is converted to 6-MP by the enzyme thiopurine S-methyltransferase and some 6-MP is converted to 6-thioguanine, or 6-TG.

Both 6-MP and 6-TG act as purine analogs, and can conjugate with ribose and then get phosphorylated to form nucleotides.

These nucleotides can mimic normal nucleotides and incorporate into DNA halting DNA replication.

Also, active metabolites of 6-MP inhibit two important enzymes in the purine synthesis: PRPP synthetase and AMP deaminase.

PRPP synthetase converts PRPP to IMP and AMP deaminase converts AMP to IMP and so the end-result is the decreased production of IMP which, remember, is the generic purine, and thus, nucleotide synthesis comes to a halt.

Notice also that allopurinol, which is an antigout medication, inhibits xanthine oxidase, which is the enzyme that metabolizes 6-MP and when azathioprine and allopurinol are used together, 6-MP increases to toxic levels.

Moving on to indications. Azathioprine is used for the treatment of leukemias, such as acute lymphoblastic leukemia, or ALL, and chronic myelogenous leukemia, or CML.

Now, an important side effect of azathioprine is bone marrow suppression which leads to pancytopenia.

When DNA synthesis is inhibited, megaloblastic anemia occurs.

This and bone marrow suppression are common to all the antimetabolites used for cancer treatment.

The decrease in white blood cells leads to immunosuppression, increased risk for infections and exacerbation of chronic infections such as hepatitis B infection and herpes zoster virus infection.

Other serious adverse effects include liver toxicity which manifests as cholestasis, or decreased bile flow, and acute pancreatitis.

Also, azathioprine is contraindicated during pregnancy due to its teratogenic effects.

Acute toxic effects of azathioprine include gastrointestinal disturbances like nausea and vomiting.

Now, cladribine is another purine analog which can inhibit DNA proliferation through various mechanisms.

Cladribine gets phosphorylated to a triphosphate form which can be incorporated into newly synthesized DNA strands.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Nomograms" D. Nicoll , C. Mark Lu, S.J. McPhee (Eds.), Guide to Diagnostic Tests, 7e. McGraw-Hill (2017)
  5. "Overview of hemostasis" J.C. Aster, H. Bunn (Eds.), Pathophysiology of Blood Disorders, 2e. McGraw-Hill. (2016)
  6. "Cytotoxic-induced heart failure among breast cancer patients in Nigeria: A call to prevent today's cancer patients from being tomorrow's cardiac patients" Annals of African Medicine (2020)
  7. "Clinical potential of midostaurin in advanced systemic mastocytosis" Blood and Lymphatic Cancer: Targets and Therapy (2017)